Marta Martín Izquierdo-rekin lankidetzan egindako argitalpenak (10)

2022

  1. TRAF3 alterations are frequent in del-3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 903-914

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

    Haematologica, Vol. 106, Núm. 8, pp. 2215-2223

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

  3. Helpful criteria when implementing ngs panels in childhood lymphoblastic leukemia

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-15

2019

  1. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains

    Experimental Hematology, Vol. 72, pp. 9-13

  2. Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing

    Annals of Medicine, Vol. 51, Núm. 2, pp. 141-148

  3. Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders

    Seminars in Thrombosis and Hemostasis, Vol. 45, Núm. 7, pp. 695-707

  4. Splice donor site sgRNAs enhance CRISPR/ Cas9-mediated knockout efficiency

    PLoS ONE, Vol. 14, Núm. 5